Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction

Last updated: January 24, 2014
Sponsor: Oslo University Hospital
Overall Status: Completed

Phase

3

Condition

Circulation Disorders

Congestive Heart Failure

Heart Disease

Treatment

N/A

Clinical Study ID

NCT00430885
175464/V50
NFR 175464/V50
  • Ages 18-18
  • All Genders

Study Summary

The instigators hypothesize that IVIG, given in the acute phase following MI in patients at risk for developing HF, will improve cardiac performance, and by attenuating cardiac remodeling in this phase, such therapy will prevent the development of chronic HF resulting in long term beneficial effect also after the therapy has been stopped.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age of 18-80 years

  • Have a recent MI (<5days)

  • Have ASAT >100 U/L or CKMB > 50 U/L.

  • Have LVEF <40%.

  • Are on optimal medical treatment and considered unsuitable for surgical intervention.

Exclusion

Exclusion Criteria:

  • Evidence of unstable disease, concomitant ischemia or unstable angina during thehospitalization.

  • Significant concomitant disease such as infections, pulmonary disease or connectivetissue disease.

  • Participating in other studies.

  • Inability to participate.

  • Diseases that require surgery.

  • Planned revascularisation.

  • Known hypersensitivity to IVIG.

Study Design

Total Participants: 62
Study Start date:
February 01, 2007
Estimated Completion Date:
May 31, 2010

Study Description

This double-blind placebo-controlled study represents a new approach to cardiovascular disease. The project deals with unresolved issues in the intersection between cardiology, immunology and molecular biology.

IVIG/placebo will be given as an induction therapy for 5 days and thereafter as monthly infusions for 5 months. Change in left ventricular remodeling will be assessed at baseline, and 6 and 12 months with MRI and echocardiography.

The objectives are:

  1. The primary objective of this study is to evaluate the effect on IVIG on LV remodeling and function: LV remodeling will be evaluated with magnetic resonance imaging (MRI) which offers an unsurpassed precision in the measurements of heart volumes and function. End points will be LV-end systolic and diastolic volume (LVESV, LVEDV), regional wall motion score index (WMSI), and LV-ejection fraction (LV-EF).

  2. The secondary objective of this study is to evaluate the effect on IVIG on the myocardial marker B-Type Natriuretic Peptide (BNP). BNP is a sensitive marker of the degree of HF besides being a prognostic indicator 18-20.

  3. The tertiary objective of this study is to evaluate the effect on IVIG on:

    a. Quality of life. b. Effect on New York Heart Association (NYHA) functional class. c. Effect on immunological variables. i. Inflammatory cytokines such as TNF-alpha, IL-6, IL-18. ii. Anti-inflammatory cytokines such as IL-10 and transforming growth factor beta iii. Chemokines such as monocyte chemoattractant protein 1, IL-8 and CCL21. iv. Regulators of hypertrophy such as matrix metalloproteinases, their endogenous inhibitors (i.e., TIMPs) and procollagen III N-terminal.

    d. Effect on neurohormones. e. Withdrawals. f. Side effects.

Connect with a study center

  • Rikshospitalet University Hospital

    Oslo,
    Norway

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.